Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair in moderate to severe persistent allergic asthma
NCT01202903Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2010
- Primary completion
- Oct 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab in allergic asthma, sponsored by Novartis. Started Sep 2010; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT01202903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01202903.